Covid 19 Research using Clinical Trials (Home Page)
Report for D008180: Lupus Erythematosus, Systemic NIH
(Synonyms: Lupus Erythematosus, Sy, Lupus Erythematosus, Syst, Lupus Erythematosus, Systemic)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (7)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug157 | COVID-19 infection Wiki | 0.58 |
| drug146 | CHLORPROMAZINE (CPZ) Wiki | 0.58 |
| drug669 | Questionnaire by phone call Wiki | 0.58 |
| drug148 | COVID 19 diagnostic test by PCR Wiki | 0.58 |
| drug773 | Standard of Care (SOC) Wiki | 0.58 |
| drug823 | Telemedicine Wiki | 0.33 |
| drug769 | Standard care Wiki | 0.29 |
Correlated MeSH Terms (10)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D015535 | Arthritis, Psoriatic NIH | 0.82 |
| D001168 | Arthritis NIH | 0.67 |
| D001167 | Arteritis NIH | 0.58 |
| D025241 | Spondylarthritis NIH | 0.58 |
| D011111 | Polymyalgia Rheumatica NIH | 0.58 |
| D013700 | Giant Cell Arteritis NIH | 0.58 |
| D012859 | Sjogren's Syndrome NIH | 0.58 |
| D003095 | Collagen Diseases NIH | 0.41 |
| D001327 | Autoimmune Diseases NIH | 0.41 |
| D012216 | Rheumatic Diseases NIH | 0.41 |
Correlated HPO Terms (0)
| Name (Synonyms) | Correlation |
|---|
There are 3 clinical trials
Clinical Trials
1 COVID-19 Infection in Vulnerable Patients With Inflammatory Rheumatic Diseases
The trial is a prospective, observational study aiming to identify risk factors for serious COVID-19 infection by evaluating clinical measures and biomarkers of inflammation in patients with inflammatory rheumatic disease hospitalized with COVID-19 compared with control groups.
NCT04335747 Rheumatoid Arthritis Psoriatic Arthritis Axial Spondyloarthritis Systemic Lupus Erythematosus Giant Cell Arteritis Other: COVID-19 infection MeSH:Arthritis Arthritis, Psoriatic Rheumatic Diseases Spondylarthritis Polymyalgia Rheumatica Giant Cell Arteritis Arteritis Lupus Erythematosus, Systemic Collagen Diseases
HPO:Arteritis Arthritis Polyarticular arthritis Systemic lupus erythematosus
Primary Outcomes
Description: The objective is to examine whether increased disease activity leads to increased risk of hospitalization due to COVID-19 in patients with inflammatory rheumatic disease
Measure: Disease activity Time: Last registration of disease activity in the medical journal before admission/inclusion
Secondary Outcomes
Description: Examine whether immune modulating treatments protect or leads to increased risk of hospitalization due to COVID-19 in patients with inflammatory rheumatic disease.
Measure: Immune modulating treatments Time: Current immune modulating treatments at admission/inclusion
Description: Identify prognostic biomarkers by comparing serology of patients with inflammatory rheumatic disease hospitalized with COVID-19 and comparing them with the two control groups
Measure: Biomarkers Time: Blood sample 1 is taken 0-3 days after inclusion and blood sample 2 is taken 2-6 weeks after blood sample 1
2 Association Between Long-term Hydroxychloroquine Treatment and Outcome of a History of Symptoms Suggestive of COVID-19 Infection During the Epidemic Period in France in Patients With Autoimmune Disease
Primary Outcomes
Description: The objective is to examine whether increased disease activity leads to increased risk of hospitalization due to COVID-19 in patients with inflammatory rheumatic disease
Measure: Disease activity Time: Last registration of disease activity in the medical journal before admission/inclusionSecondary Outcomes
Description: Examine whether immune modulating treatments protect or leads to increased risk of hospitalization due to COVID-19 in patients with inflammatory rheumatic disease.
Measure: Immune modulating treatments Time: Current immune modulating treatments at admission/inclusionDescription: Identify prognostic biomarkers by comparing serology of patients with inflammatory rheumatic disease hospitalized with COVID-19 and comparing them with the two control groups
Measure: Biomarkers Time: Blood sample 1 is taken 0-3 days after inclusion and blood sample 2 is taken 2-6 weeks after blood sample 1This epidemiological, transversal, cohort study aims to determine the potential influence of an active long-term hydroxychloroquine intake over the prevalence of a history of symptoms evocative of a COVID-19 infection in patients with a history of systemic lupus erythematosus, rheumatoid arthritis, Sjogren's syndrome or psoriatic arthritis, during the epidemic period in France. The information is gathered using a standardized questionnaire, by phone call.
NCT04345159 SARS-CoV-2 Systemic Lupus Erythematosus Rheumatoid Arthritis Sjogren's Syndrome Psoriatic Arthritis Other: Questionnaire by phone call MeSH:Arthritis Arthritis, Psoriatic Sjogren's Syndrome Lupus Erythematosus, Systemic Autoimmune Diseases
HPO:Arthritis Autoimmunity Polyarticular arthritis Systemic lupus erythematosus
Primary Outcomes
Description: Adjusted Odds Ratio measuring the association between an exposure to long-term hydroxychloroquine intake and a history of symptoms compatible with a COVID-19 infection.
Measure: Adjusted Odds Ratio Time: 4 months after inclusion
3 Use of Telemedicine for Follow-up of Systemic Lupus Erythematosus ("TeleSLE") in the COVID-19 Outbreak: a Pragmatic Randomised Controlled Trial
Primary Outcomes
Description: Adjusted Odds Ratio measuring the association between an exposure to long-term hydroxychloroquine intake and a history of symptoms compatible with a COVID-19 infection.
Measure: Adjusted Odds Ratio Time: 4 months after inclusionBackground Patients with systemic lupus erythematosus (SLE) might be more susceptible to Covid-19 due to the underlying disease, co-morbidities and the use of immunosuppressive drugs. We hypothesize that telemedicine (TM) can be an effective mode of health-care delivery minimizing the risk of SARS-CoV-2 exposure, while maintaining disease control in these patients. Objectives The primary aim of this study is to evaluate the effectiveness to achieve remission or lupus low disease activity state (LLDAS) using TM delivered care compared to conventional in-person outpatient follow-up in SLE. The secondary objectives are to compare the patient reported outcomes and cost between the two modes of health care delivery. Study design This is a 12-months single centered pragmatic randomized controlled study. A total of 150 enrolled patients with SLE being followed at the Prince of Wales Hospital rheumatology clinics will be randomized to either TM (TM group) or standard care (SC group) in a 1:1 ratio. Patients in the TM group will receive scheduled follow-ups via videoconferencing using a custom-made mobile app. SC group patients will continue conventional standard in-person outpatient care. The disease and patient reported outcomes as well as the health care related costs will be compared. Expected outcomes Data from this study will support the notion that TM based care is as effective as conventional in-person care in achieving disease remission or LLDAS, as well as addressing psychosocial implications to ensure the best possible care for our patients in a cost-effective manner during this pandemic.
NCT04368299 SLE Other: Telemedicine Other: Standard care MeSH:Lupus Erythematosus, Systemic
HPO:Systemic lupus erythematosus
Primary Outcomes
Measure: The percentage of patients in remission or LLDAS at one year. Time: 1 year
Secondary Outcomes
Measure: Direct and indirect costs after one year. Time: 1 year
Description: LupusQoL evaluates 8 domains including physical health, pain, planning, intimate relationships, burden to others, emotional health, body image, and fatigue. Questionnaire has a 5-point Likert response format (0=all the time, 1=most of the time, 2=a good bit of the time, 3=occasionally, and 4=never). Higher score means better quality of life.
Measure: The change of Lupus Quality of Life (LupusQoL) at one year. Time: 1 year
Description: They are in a 5-point Likert response format (0=strongly disagree, 1=disagree, 2=neutral, 3=agree, and 4=strongly agree). Higher score means more confident and satisfied.
Measure: Patient confidence and satisfaction score at one year. Time: 1 year
Measure: Rates of adverse reaction and severe adverse reaction, including contracting COVID-19 infection, after one year. Time: 1 year
Measure: Numbers of clinic visits, hospitalization, overall in-person hospital visits in one year. Time: 1 year
Description: HAQ-DI covers various common daily activities to assess disability.It consists of 8 questions. Each question asks on a scale ranging from 0 to 3 if the categories can be performed without any difficulty (scale 0) up to cannot be done at all (scale 3). Higher score means higher disability.
Measure: The change of (Health Assessment Questionnaire Disability Index HAQ-DI) at one year. Time: 1 year
Description: HADS was developed to assess anxiety and depression in medical patients. Each domain has 7 items. Each item are answered by the patient on a four point (0-3) response category so the possible scores ranged from 0 to 21 for anxiety and 0 to 21 for depression. Higher score means more likely the patient has anxiety or depression.
Measure: The change of (Hospital Anxiety and Depression Scale) HADS at one year. Time: 1 year
HPO Nodes
Primary Outcomes
Measure: The percentage of patients in remission or LLDAS at one year. Time: 1 yearSecondary Outcomes
Measure: Direct and indirect costs after one year. Time: 1 yearDescription: LupusQoL evaluates 8 domains including physical health, pain, planning, intimate relationships, burden to others, emotional health, body image, and fatigue. Questionnaire has a 5-point Likert response format (0=all the time, 1=most of the time, 2=a good bit of the time, 3=occasionally, and 4=never). Higher score means better quality of life.
Measure: The change of Lupus Quality of Life (LupusQoL) at one year. Time: 1 yearDescription: They are in a 5-point Likert response format (0=strongly disagree, 1=disagree, 2=neutral, 3=agree, and 4=strongly agree). Higher score means more confident and satisfied.
Measure: Patient confidence and satisfaction score at one year. Time: 1 yearMeasure: Rates of adverse reaction and severe adverse reaction, including contracting COVID-19 infection, after one year. Time: 1 year
Measure: Numbers of clinic visits, hospitalization, overall in-person hospital visits in one year. Time: 1 year
Description: HAQ-DI covers various common daily activities to assess disability.It consists of 8 questions. Each question asks on a scale ranging from 0 to 3 if the categories can be performed without any difficulty (scale 0) up to cannot be done at all (scale 3). Higher score means higher disability.
Measure: The change of (Health Assessment Questionnaire Disability Index HAQ-DI) at one year. Time: 1 yearDescription: HADS was developed to assess anxiety and depression in medical patients. Each domain has 7 items. Each item are answered by the patient on a four point (0-3) response category so the possible scores ranged from 0 to 21 for anxiety and 0 to 21 for depression. Higher score means more likely the patient has anxiety or depression.
Measure: The change of (Hospital Anxiety and Depression Scale) HADS at one year. Time: 1 year